10月14日 - ** 癌症疗法开发商 Senti Biosciences SNTI.O 股价盘前上涨 1.1% 至 1.70 美元
** H.C. Wainwright开始给予 "买入 "评级，目标价为12美元，比该股上次收盘价上涨约614%。
** 券商称 Senti 的新型细胞疗法有助于治疗难治的血癌患者
** 认为该公司的治疗平台 "具有治疗多种癌症类型的潜力，包括血液恶性肿瘤和实体瘤"。
** SNTI正在开发一种细胞疗法，用于治疗急性髓性白血病，这是一种生长迅速、治疗手段有限的血癌。
** 两家券商中的两家将该股评级为 "买入 "或更高，没有一家评级为 "持有 "或 "卖出"；其目标价中位数为 13.50 美元
** 截至上次收盘，该股今年累计下跌约 52
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.